BioCancell is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer in areas of unmet need. Our initial program is the genetic therapy for early stage bladder cancer. Our most advanced investigational agent, BC-819, is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC). BC-819 has been tested in three clinical trials to date, and it is planned that two registrational trials will be initiated in 2017 and will begin enrolling patients in the first half of 2018.
BioCancell is located in Cambridge, Massachusetts, and in Jerusalem. It is publicly traded on the Tel Aviv Stock Exchange (TASE:BICL).
BioCancell’s R&D activities build upon the research of Professor Abraham Hochberg of the Hebrew University of Jerusalem. Professor Hochberg isolated the human H19 gene and determined that the gene is expressed in over forty different forms of cancer, while being quiescent in normal adult tissues. H19-based therapy combines a highly selective method of killing cancer cells with a favorable safety profile. Each of BioCancell’s product candidates relies on a proprietary H19 technology platform, with the potential to provide benefits that are competitive with existing cancer treatment methods.
We are dedicated to the discovery, development and commercialization of effective and safe treatment for cancer that address significant unmet medical needs and provide clinical benefits to millions of patients worldwide.